Compare GOAI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOAI | NTHI |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | 3 | 5 |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.5M | 139.1M |
| IPO Year | N/A | N/A |
| Metric | GOAI | NTHI |
|---|---|---|
| Price | $3.40 | $5.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 69.4K | ★ 105.5K |
| Earning Date | 04-10-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.75 | $3.20 |
| 52 Week High | $6.67 | $12.99 |
| Indicator | GOAI | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 49.35 |
| Support Level | $3.48 | $5.25 |
| Resistance Level | $4.36 | $5.70 |
| Average True Range (ATR) | 0.26 | 0.68 |
| MACD | -0.02 | 0.13 |
| Stochastic Oscillator | 31.75 | 50.35 |
Eva Live Inc is a United States-based technology company that has developed an automated and intelligent advertiser campaign management platform, Eva Platform, which enables advertisers ('customers, clients') to buy advertising space on several digital channels to reach their desired audience. The company also works with Businesses that utilize its in-house digital marketing capabilities, including advice, creative services, account management, production of advertising materials, media planning, and buying.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.